| Name | Title | Contact Details |
|---|
The Turnaround Team is a Westfield, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Dogwood Forest Of Alpharetta is a Alpharetta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Boehringer Ingelheim Vetmedica, Inc., a subsidiary of Boehringer Ingelheim Corporation since 1981, is headquartered in St. Joseph, MO. From four sites, St. Joseph, MO, Elwood, KS, Sioux Center, IA, and Ames, IA, this USA subsidiary acts as a center of
Mercyhealth is a regional health system with over 700 employed physician partners, seven hospitals and 85 primary and specialty care locations throughout 50 northern Illinois and southern Wisconsin communities. We are committed to being a top integrated health care provider and continuously work to make life better for the people, families and communities we serve. As an integrated health care provider, we provide exceptional, coordinated health care that spans four core service divisions: hospital-based services, clinic-based services, post-acute care and retail services, and a wholly owned insurance company. These four core service divisions make up our comprehensive, vertically integrated delivery system, and integrated delivery is what makes Mercyhealth unique in serving the full range of health care needs for our patients. Every day, our 8,000+ employee take to heart our passion for making lives better. Our providers, nurses and partners are committed to working together to make lives better for our patients and their families. Touching lives invigorates, inspires and drives us to do our very best, and we continuously look for ways to make each life better with the utmost care and professionalism. This can be as complex as a cutting-edge procedure or as simple as a smile. Nothing is ever too small or taken for granted. Everything matters. And we never miss a beat.
Blueprint Medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. Our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets. We are boldly advancing a deep pipeline of highly targeted therapies against previously unaddressed drivers of disease. By focusing on genomically defined subsets of patients, we believe we can identify the people most likely to respond to our therapies, resulting in a more efficient clinical development path with a greater likelihood of success and better outcomes for patients. We see a substantial opportunity in kinase drug discovery and development to deliver breakthrough medicines that allow patients to live longer with better quality of life and prevent recurrences of disease. Kinases are involved in many hallmarks of tumor biology and are proven cancer drug targets. Currently approved drugs focus on less than 5 percent of known kinases, and the function of most kinases is unknown. Led by a team of industry innovators with a track record of bringing life-changing drugs to market, we believe Blueprint Medicines has the experience and expertise to deliver on the tremendous untapped potential of kinase therapies to improve patients’ lives. We don’t think in small steps. We think in giant leaps. We are driven by the pursuit of new ideas, new innovations, and new ways of thinking.